Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant botulinum toxin type A - JHM Biopharma

Next Previous
Drug Profile

Recombinant botulinum toxin type A - JHM Biopharma

Alternative Names: Eveotox; JHM-03

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JHM BioPharma (Tonghua)
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Antispastics; Anxiolytics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Gastrokinetics; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glabellar lines; Muscle spasticity

Most Recent Events

  • 11 Dec 2025 Phase-III clinical trials in Muscle spasticity (Treatment-experienced) in China (IM) (NCT07242300)
  • 21 Nov 2025 JHM BioPharma plans a phase III trial for Muscle spasticity in China (Parenteral) (NCT07242300)
  • 23 Jul 2025 JHM BioPharma completes a phase I/II trial in Muscle spasticity in China (IM) (NCT06584240)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top